This is from a reader.
Subject: Exciting Multiple Myeloma Data at ASH
Message: Hi Beth,
Here are some data highlights from The 50th Annual American Society
of Hematology (ASH) Meeting this week:
- Updated results from the ECOG study evaluating Revlimid plus low-dose dexamethasone in newly diagnosed patients was presented by Dr. Rajkumar in a joint symposium of the American Society of Clinical Oncology and ASH. The results are the highest 3 year overall survival rates ever reported in this patient group.
- Data presented by Dr. San Miguel showed that relapsed/refractory patients who received continuous treatment with Revlimid and dexamethasone after achieving their best response lived longer and had increased time to disease progression compared to those who discontinued treatment after ten months or less.
- Dr. Lacy presented data which showed that pomalidomide with dexamethasone has promising activity for patients with relapsed/refractory MM. Results from this ongoing trial showed high remission rates.
I’m in Dr. Lacy’s study of pomalidomide (CC-4047) and I can tell you she is enthusiastic about it.
Hand-wringing at the premiere international hematology meeting over whether chemotherapy alone really is as good as stem cell transplant for multiple myeloma.